Food and Drug Administration
Oncologic Drugs Advisory Committee
February 27, 2002
Briefing Information
Isses in the Clinical Development of Investigational Agents Being Evaluated for the Post-Surgical Adjuant Treatment of High-Risk (Stages IIb and III) Melanoma pdf htm doc
Appropriate Study Design and Control for the Proposed Phase
3 Trial of
Investigational New Drug (IND) 2885, Melacine® (melanoma vaccine), Corixa
Corporation, for adjuvant treatment of melanoma pdf